WGRX PAID ADVERTORIAL*
NASDAQ: WGRX
Wellgistics Health, Inc. — Building a Vertically Integrated, AI-Powered Prescription Drug Infrastructure Platform in the $634B U.S. Market [i]
Connecting Manufacturers, Pharmacies, Employers, and Patients Through an End-to-End Distribution, EinsteinRx™ AI Hub, and PharmacyChain™ Smart Contract Ecosystem Designed to Enhance Transparency, Efficiency, and Prescription Access at National Scale. [ii]
Scroll
📊 Key Metrics
Financial & Operational Highlights
$600M+
$600M+ Lifetime Drug Sales [ii]
6,500+
6,500+ Pharmacies Nationwide [ii]
200+
200+ Manufacturer Relationships [ii]
50 States
Licensed & NABP Accredited in All 50 States [ii]
$8.1M
$8.1M Debt Converted to Equity (Strengthened Balance Sheet) [iii]
500/mo
Targeting Onboarding of Up to 500 Pharmacies Per Month by YE 2026 [iv]
⚠ Market Challenge
The Prescription Drug Market Is Structurally Inefficient
🔴 Problem
A $634B+ Market Dominated by Intermediaries and Misaligned Incentives [i]
The U.S. prescription drug market exceeds $634 billion annually, yet more than 95% of pricing and access is controlled by a handful of PBMs extracting rebates and limiting transparency.
The consequences are systemic: [ii]
$330B+ in annual rebates
Rarely reaching patients or employers
32% of prescriptions never filled
Due to cost, delays, or denials
Independent pharmacies closing
At over 1,000 per year
Employers facing 8–10% annual increases
In pharmacy spend each year
1 in 3 adults skipping medications
Due to affordability
🏭
Manufacturers lose margin and visibility.
🏪
Pharmacies lose profitability.
💼
Employers lack cost transparency.
👤
Patients face delays and rising out-of-pocket costs.
The pharmaceutical supply chain is fragmented, opaque, and inefficient.
🟢 Solution
A Vertically Integrated, AI-Powered Prescription Infrastructure Platform
Wellgistics Health is building a vertically integrated ecosystem connecting:
Manufacturer
➔
Provider
➔
WGRX Hub
➔
Pharmacy
➔
Patient
Powered by EinsteinRx™ and HubRx AI, the platform integrates wholesale distribution, AI-driven prescription optimization, and blockchain-enabled infrastructure to streamline the entire prescription lifecycle. [ii]
The solution is built on a three-part ecosystem:
Wellgistics Distribution
50-state NABP-accredited wholesale & 3PL network serving 6,500+ independent pharmacies.
Wellgistics Tech & Hub
AI-powered prescription routing, automation, and clinical coordination platform.
Wellgistics Pharmacy
Multi-state licensed direct-to-patient dispensing and centralized fulfillment hub.
Key advantages include:
Direct-to-Patient Rail
Reduces reliance on traditional PBM intermediaries.
Empowered Independent Pharmacies
Enhances revenue opportunities and fulfillment capabilities across a 6,500+ pharmacy network. [ii]
Transparent Pricing
Improves cost visibility for employers and payors.
Better Outcomes
Faster prescription routing, lower friction in prior authorizations, reduced delays, and improved adherence.
📈 Market Opportunity
A Multi-Billion Dollar Market Opportunity Across Prescription Infrastructure & Healthcare Technology
Wellgistics Health operates within the $634.32 billion U.S. prescription drug market, projected to grow to $883.97 billion by 2030 [i] at a 5.72% CAGR, forming the core infrastructure opportunity for its vertically integrated platform.
Within this broader market, key therapeutic segments provide additional scale, including the $48 billion U.S. diabetes market expected to reach $79 billion by 2031 [v], the $53 billion North American GLP-1 market projected to grow to $156 billion by 2030 [vi], and the $46 billion U.S. cardiometabolic disorders market forecasted to expand to $85 billion by 2031 [vi]
Supporting long-term infrastructure expansion, the blockchain in healthcare market is projected to grow from $11 billion today to $214 billion by 2030 [vi], while the mental health software market is expected to increase from $6.3 billion in 2025 to $18.1 billion by 2033 [vii], and the telemedicine remote dispensing market is forecasted to grow from $6.7 billion in 2025 to $13.57 billion by 2032 [viii].
Collectively, these markets represent substantial and expanding addressable opportunities across prescription distribution, chronic disease management, AI-driven optimization, and digital healthcare infrastructure.
Wellgistics Health Strategically Positioned to Participate in Multi-Billion Dollar Growth Across Prescription Drugs, GLP-1, and Healthcare Technology Markets
🚀 Strategic Initiative
Strategic Expansion Initiative
Wellgistics Health to Add Telehealth & Mental Health AI Capabilities via Tollo Health Partnership Expansion [ix]
Tollo Health recently formed subsidiary TolloCare, LLC ('TolloCare') initially targeted to provide telehealth services for GLP-1 and Long COVID patients
TolloCare has white-labeled telehealth capabilities via a telemedicine company with over 5,000 onboarded physicians nationwide to provide synchronous and asynchronous medical services, including prescriptions, for weight loss and separately will cultivate a Long COVID physician base
Tollo Health has entered into agreement to expand TolloCare capabilities via a partnership with a stealth San Francisco Bay Area startup preparing to deploy a mental health AI app with unique tools to engage with patients
"More and more patients are interacting with their healthcare professionals primarily online. As Wellgistics Health evolves its business model from pharmaceutical distribution-only to a more comprehensive patient service platform through the Wellgistics Pharmacy Network and its online pharmacy, the company recognizes the importance of meeting patients where they are and delivering convenient solutions designed to improve outcomes. GLP-1 agonist drug utilization continues to expand, particularly as oral formulations enter the market. With Forzet™ distribution commencing this quarter, Wellgistics Health believes the timing is appropriate to expand into telemedicine. Tollo Health has established itself as an intellectual leader in essential amino acid formulations and mitochondrial biology. Leveraging Tollo Health's expertise supports physician and pharmacist education on optimizing GLP-1 agonist therapy alongside Forzet™."
🔒 Technology Catalyst
Technology Infrastructure Catalyst
Wellgistics Health Adds Quantum Key Encryption to PharmacyChain(TM) AI-Enabled Blockchain Smart Contract Partnership with DataVault AI [x]
The companies have successfully completed the feasibility assessment phase and established key milestones toward pilot deployment by year-end 2026:
Q1
End of Q1 2026
Complete initial selection of which blockchain platforms are most suitable for the initial deployment of PharmacyChain by the end of the first quarter of 2026;
Q2
End of Q2 2026
Establish the 'closed loop' initial HIPAA-compliant data transfers required to close a smart contract-enabled prescription drug transactions (the 'PharmacyChain Contract') via Wellgistics' own pharmacy by the end of the second quarter of 2026;
Q3
End of Q3 2026
Successfully close a PharmacyChain Contract via a pilot program with an early adopter pharmacy from among Wellgistics' 6,500 independent pharmacy clients (the 'Wellgistics Pharmacy Network') by the end of the third quarter of 2026;
Q4
Year-End 2026
Begin to expand marketing of PharmacyChain to the entire Wellgistics Pharmacy Network by year-end 2026.
"Partnering with DataVault AI represented a crucial step forward for Wellgistics as the company prepares to deploy its technologies to modernize the U.S. prescription drug ecosystem. DataVault AI's technology platform is uniquely positioned to enable secure, scalable tokenization that complements EinsteinRx™ AI and PharmacyChain™ smart contracts. This combination is designed to deliver enhanced transparency, operational efficiency, and fraud prevention across the Wellgistics pharmacy network—from optimized drug selection and adherence support to streamlined payments and waste reduction. The validated strength of DataVault AI's intellectual property and platform provides critical regulatory guardrails in an evolving compliance landscape. As implementation advances, Wellgistics anticipates meaningful improvements in pharmacy profitability, patient safety, and overall healthcare delivery."
💬 Investors
Greetings Investors*,
Wellgistics Health, Inc. (NASDAQ:WGRX) continues to advance a vertically integrated prescription infrastructure platform combining nationwide distribution, AI-powered automation, and smart contract enablement. The company is focused on modernizing prescription logistics while strengthening independent pharmacy economics.
Today, the platform supports 6,500+ pharmacies, 200+ manufacturer relationships, and more than 12,500 products/NDCs, reflecting growing operational scale and supplier expansion across key therapeutic categories.
Technology remains central to execution, powered by three full-stack platforms: EinsteinRx™, HubRx AI, and PharmacyChain™, designed to optimize prescription routing, automate workflows, and enhance transparency across stakeholders.
Through disciplined integration and strategic partnerships, Wellgistics Health continues to scale infrastructure, expand capabilities, and reinforce its position within the evolving prescription ecosystem.
* See our Important Notice and Disclaimer below for a detailed discussion on compensation, risks, the risks associated with forward looking statements, the need to seek the advice of a professional investment advisor before investing, and more.
⭐ Top Picks
Top Reasons to Have WGRX on Your Radar
01
Operating in a $634B U.S. Prescription Drug Market
Core exposure to one of the largest healthcare markets, projected to approach $884B by 2030. [i]
02
Proven Sales History
$600M+ in lifetime drug sales demonstrating operational execution beyond early-stage development. [ii]
03
Nationwide Pharmacy Network at Scale
6,500+ independent pharmacies engaged, covering roughly one-third of U.S. independents. [ii]
04
Aggressive Network Expansion Target
Management targeting onboarding of up to 500 pharmacies per month into the formal Wellgistics Pharmacy Network by year-end 2026. [iv]
05
200+ Manufacturer Relationships & 12,500+ Products
Expanding supplier base and diversified product catalog across high-demand therapeutic categories. [ii]
06
Launch of Brenzavvy® Diabetes Therapy
Commercial rollout targeting the multi-billion-dollar SGLT-2 diabetes market with AI-enabled pharmacy optimization support.
07
Three Proprietary Technology Platforms
EinsteinRx™, HubRx AI, and PharmacyChain™ forming a full-stack AI and smart contract prescription infrastructure. [ii]
08
Three-Part Integrated Health Solution
Wellgistics Distribution + Wellgistics Tech & Hub + Wellgistics Pharmacy forming a vertically integrated prescription ecosystem. [ii]
09
Multiple Revenue Streams
Wholesale distribution margins, pharmacy fulfillment fees, SaaS platform fees, hub service fees, subscription models, AI analytics, and employer carve-out programs. [ii]
10
Strategic Partnerships & Ecosystem Expansion
Collaborations with DataVault AI (blockchain IP licensing), TheracosBio (Brenzavvy® diabetes launch), Tollo Health & TolloCare (GLP-1 companion and telehealth expansion), NFL Alumni Health (program deployment), and RxERP Financial (pharmacy capital access program) support technology integration, therapeutic expansion, and network scalability across the prescription ecosystem. [x] [xi] [v]
11
Clear Growth Roadmap
Expansion of vertically integrated distribution, scaling AI deployment, telehealth integration, smart contract rollout, and strategic acquisitions across prescription logistics verticals. [ii]
🏢 Company
Company Overview
Wellgistics Health — A Vertically Integrated, AI-Powered Prescription Infrastructure Platform
Wellgistics Health (NASDAQ:WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispending journey.
Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network") and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access.
Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.
6,500+
Pharmacies Connected
200+
Manufacturers
12,500+
Products / NDCs
50
States Licensed
Landmark support for PBM reform at Federal & State level
Current administration has clearly expressed its support for:
Lowering the cost of prescription drugs
Fair, transparent & open markets
Patient costs transparency
Open competition
Health equity with patient access
Wellgistics Health's commitment to faster, more affordable, and more transparent prescription care aligns directly with the administration's policy goals
Our Three Verticals
This ecosystem has three components:
Distribution Arm
Comprised of a licensed wholesale facility that buys direct from over 200 pharma manufacturers and supplies inventory to more than 6,500 pharmacies nationwide across all 50 states.
Pharmacy & Partner Network
Delivers insurance and cash-pay options, DTC programs, and data capture through in-house and partner pharmacies.
Tech & Hub Division
Prescription routing technology, full concierge services, managed care programs, patient access such as eligibility, benefits verification, prior authorizations, denials, and ongoing adherence and support services.
Technology (Underlying Magic)
The Rails of Modern Prescription Delivery
Leveraging AI to make our process faster, simpler and easier
Launched in 2025
HubRx AI integrated with our existing tech stack
Improve Patient Access with Key Components:
AI Consent
AI Enrollment
AI Benefit Verification
AI Prior Authorization
AI Copay Assistance
AI Customer Service
AI Sales
Business Model
Multiple
Revenue Streams
Distribution Center:
Sales of Rx Products to Pharmacies
Pharmacy Center:
DTP, Fulfillment Models, White Label, Cash Pay, Telemedicine
Model:
High-Volume Distribution + Recurring SaaS = Scalable Revenue, Low Dilution Growth
Hub Services:
Fees for Services (benefit management, prior authorizations, patient support, etc.)
Technology:
SaaS Fees, Rx Routing, Data Fees, Subscription Models for AI Services
Competition / Differentiators
Why We Win
PBMs/Big 3:
Opaque Rebates
Spread Pricing
Misaligned Incentives
WGRX:
Transparent
AI-Driven
Vertically Integrated
Aligned with all Stakeholders
Differentiators:
Proprietary Routing (Wellgistics Hub)
SaaS-Model for AI Agents (HubRx AI)
AI-Underwriting (EinsteinRx™)
Blockchain Enabled Smart Contract (PharmacyChain™)
Employer CAA/ERISA Compliance Baked In
Multi-State Licensed Pharmacy
Integrated Claims Adjudication
Data Advantage (Routing + Adjudication Generates Proprietary Insights)
Future Growth Plans
Expand our vertically integrated pharmacy and distribution network
Accelerate direct-to-patient (DTP) programs with manufacturer partnerships to deliver lower-cost, higher-access prescriptions
Grow employer carve-out solutions to increase transparency and affordability in prescription benefits
Deploy AI-powered technologies like EinsteinRx™, HubRx AI, and PharmacyChain™ at national scale
Drive strategic partnerships with manufacturers, employer groups, and healthcare organizations
Unified Tech Platform
Our fully-integrated ecosystem connects every touchpoint, enabling:
Seamless Pharmacy Operations
Direct Manufacturer Fulfillment
Full Patient Savings Transparency
Better Patient Access
Core Vertical Services:
Distribution
40,000 sq ft licensed wholesale facility in full FDA, NABP & DSCSA compliance
Direct purchase from 200+ manufacturers—brand & generic
Licensed to operate in all 50 states
Direct-to-pharmacy & direct-to-patient delivery capability
Serialized ERP technology for end-to-end drug tracking - Rapid fulfillment with just-in-time inventory controls
Core Vertical Services:
Pharmacy
& Network
Full In-House Dispensing Pharmacy
DTP delivery + tracking
6,500+ Pharmacy Partners nationwide
Specialized programs for diabetes, weight loss, cardiometabolic, and more
Custom packaging & white-label fulfillment programs
Core Vertical Services:
Tech & Hub
EinsteinRx™ – Real-time analytics for prescribers, payers, and pharmacies
Eligibility, enrollments, denials, adherence—all automated
AI Prior Auth, AI Benefit Verification, AI Copay Assistance
First-party data capture + predictive cost containment insights
HubRx AI – AI Technology Based SaaS, membership, licensing based monthly fees and services
PharmacyChain™ - Blockchain technology enabling Smart Contract for all supply chain stakeholders with tokenization
Expert Leaders in Growth Execution
Prashant Patel, RPh
CEO & President
Co-Founder, Director, President and COO of TRxADE Health, Inc. Pioneered innovative technology for secondary distribution, reverse distribution, and logistics.
Eric Sherb
Chief Financial Officer
Founder and Owner of EMS Consulting Services, with previous experiences at PwC, RBSM LLP, and CFGI, with core expertise in technical advisory on complex transactions, debt/equity financing, M&A, auditing, and IPO readiness.
Dr. Shafaat Pirani, PharmD, BCGP
Chief Clinical Officer
Former Chief Clinical & Regulatory Compliance Officer for Bonum Health and TRxADE Health, Inc., with prior roles as EVP of Alliance Pharma Solutions, and Director of Operations for a PBM-affiliated independent mail-order pharmacy.
Srini Kalla
Chief Technology Officer
Former Vice President of IT at OptumRx (UHG) and Principal at Elevance Health, with focus on pharmacy and PBM healthcare technology, and leading various technology initiatives and M&A.
Nikul Panchal, RPh, BCNP
Chief Pharmacy Officer
Former Head of Operations at Tollo Health, with prior roles as VP of Pharmacy Operations at TRxADE Health, Inc., Owner of Community Specialty Pharmacy, and Radio Pharmacy Manager for GE Healthcare Diagnostics.
Latest News
Recent press coverage & announcements
Expansion
Wellgistics Health Targets Expansion into $6.3 Billion Mental Health Software Market with Strategic Investment into Stealth Mental Health AI Startup
Feb 18, 2026
AI & Telehealth
Wellgistics Health to Add Telehealth & Mental Health AI Capabilities via Tollo Health Partnership Expansion
Feb 11, 2026
Partnership
NFL Alumni Health Partners with Wellgistics Health to Deploy Technology to Improve Health Outcomes for Former NFL Players and Rural Communities
Feb 9, 2026
Blockchain
Wellgistics Health Adds Quantum Key Encryption to PharmacyChain(TM) AI-Enabled Blockchain Smart Contract Partnership with DataVault AI
Jan 12, 2026
Corporate
Wellgistics Health Provides 2026 Corporate Outlook
Jan 7, 2026
Shareholders
Wellgistics Health Reminds Shareholders of December 19, 2025 Record Date for Dream Bowl 2026 Meme Coin Tokens
Dec 17, 2025
In Summary
Wellgistics Health, Inc. (NASDAQ: WGRX) operates within the $634B U.S. prescription drug market through a vertically integrated platform connecting Manufacturer → Provider → Hub → Pharmacy → Patient. The company combines nationwide wholesale distribution, AI-powered prescription optimization, and blockchain-enabled smart contract infrastructure to modernize prescription logistics.
The platform supports 6,500+ pharmacies, 200+ manufacturer relationships, and more than 12,500 products/NDCs, with over $600M in lifetime drug sales demonstrating operational scale and execution capability.
Technology leadership is anchored by three proprietary platforms — EinsteinRx™, HubRx AI, and PharmacyChain™ — designed to enhance routing efficiency, transparency, adherence, and reimbursement workflows.
With a target of onboarding up to 500 pharmacies per month by year-end 2026, diversified revenue streams, strategic partnerships, and therapeutic expansion including the launch of Brenzavvy®, Wellgistics Health continues to scale its prescription infrastructure model.
* See our Important Notice and Disclaimer below for a detailed discussion on compensation, risks, the risks associated with forward looking statements, the need to seek the advice of a professional investment advisor before investing, and more.
Wellgistics Health Inc. (NASDAQ: WGRX) — A Vertically Integrated, AI-Enabled Prescription Infrastructure Platform
A Stock to Keep on Your Radar
Learn More →
Source
i - https://www.grandviewresearch.com/industry-analysis/us-pharmaceuticals-market-report
ii - https://wellgisticshealth.com/wp-content/uploads/2026/02/Wellgistics-Health_Wellgistics-Full-Deck.pdf
iii - https://finance.yahoo.com/news/wellgistics-health-converts-8-1m-114500581.html
iv - https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/wellgistics-health-provides-2026-corporate-outlook-1124873
v - https://www.accessnewswire.com/newsroom/en/blockchain-and-cryptocurrency/wellgistics-health-adds-quantum-key-encryption-to-pharmacychaintm-ai-1125963
vi - https://www.newswire.com/news/wellgistics-health-targets-expansion-into-6-3-billion-mental-health-software
vii - https://finance.yahoo.com/news/wellgistics-health-enters-loi-acquire-110000329.html
viii - https://www.newswire.com/news/wellgistics-health-to-add-telehealth-mental-health-ai-capabilities-via-tollo
ix - https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/wellgistics-health-announces-launch-of-diabetes-drug-brenzavvyr-to-we-1115365
x - https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/nfl-alumni-health-partners-with-wellgistics-health-to-deploy-technolo-1134809
xi - https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/wellgistics-health-launches-capital-access-program-for-6-500-pharmaci-1077151
IMPORTANT NOTICE AND DISCLAIMER
Issuer-paid advertisement. Wellgistics Health, Inc. (“WGRX” or the “Company”) has paid Publisher SmallCapsDaily, $2,500 Dollars Cash for marketing services including communicating information about the Company to the Public. This advertorial (“advertisement” or “Advertorial”) is part of those issuer-paid marketing services. The contract with WGRX was effective on 2/23/2026 and continue for 1 month (the “Term”) unless it is terminated by written notice of either party prior to the end of the Term or extended. As a result of this advertisement and other marketing efforts, Publisher also may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, Publisher holds no securities of the Company and does not intend to purchase any securities during the Term. This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of WGRX, increased trading volume, and possibly an increased share price of the WGRX’s securities, which may or may not be temporary and decrease once the marketing services have ended.
For Educational and Information Purposes Only; Not Investment Advice. This advertisement is for educational, informational and entertainment purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Publisher cannot guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of this Company or any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the Company that is the subject of the Advertorial or any other companies mentioned in this Advertorial, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this Advertorial or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision.
SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in the securities of the Company profiled in the Advertorial or any securities of the companies mentioned in this advertisement should do so with caution. Although this advertisement focuses on the positive features of the Company profiled and its securities, you must keep in mind that investing or transacting in these or any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement at most as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments.
Not an Investment Advisor or Registered Broker. Neither Publisher, or any of their owners, employees or independent contractors is currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization.
USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Publisher does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the Company profiled in the Advertorial at https://www.sec.gov/edgar/search/#/ciks=0002030763&entityName=Wellgistics%2520Health%252C%2520Inc.%2520(WGRX)%2520(CIK%25200002030763)
TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied.
